

## Lyka Labs announces FY17 Financial Results

FY17 Revenues at ₹ 119.04 Crores  
EBIDTA at ₹ 23.99 Crores

**Mumbai, 29<sup>th</sup> May, 2017:** Lyka Labs Limited, a pharmaceutical company with business across 46 countries globally in super specialty segments of Injections and Dermatology today announced its Financial Results for the Financial Year ended 31<sup>st</sup> March 2017.

### Financial Results

#### Q4FY17 (Quarter Ended 31<sup>st</sup> March 2017) – Standalone

- Revenue was at ₹ **19.47 Crores**.
- EBIDTA Margin at **29.84% (₹5.81 Crores)** compared to 21.55% (₹4.63 Crores) in Q3FY16 and 35.32% (₹8.43 Crores) in Q3FY17.
- Finance Cost was **down at ₹ 3.08 Crores** compared to ₹ 3.77 Crores in Q3FY16 and ₹ 4.44 in Q3FY17
- Net Profit at ₹ **1.04 Crores**

#### FY17 (Year Ended 31<sup>st</sup> March 2017) - Standalone

- Revenue was at ₹ **80.30 Crores**
- EBIDTA Margin at **27.61% (₹22.17 Crores)** compared to 27.99% (₹19.18 Crores) in FY16
- Net Profit at ₹ **56.87 Lacs**

#### Q4FY17 (Quarter Ended 31<sup>st</sup> March 2017) – Consolidated

- Revenue was at ₹ **32.48 Crores**
- EBIDTA Margin at **21.38% (₹6.94 Crores)** compared to 11.89% (₹4.13 Crores) in Q3FY16 and 20.48% (₹6.55 Crores) in Q3FY17.
- Finance Cost was **down at ₹ 3.62 Crores** compared to ₹ 4.50 Crores in Q3FY16 and ₹ 5.04 Crores in Q3FY17
- Net Profit at ₹ **1.84 Crores** compared to ₹ **-2.88 Crores in Q3FY17**.

#### FY17 (Year Ended 31<sup>st</sup> March 2017) – Consolidated

- Revenue was at ₹ **119.04 Crores**
- EBIDTA Margin at **20.15% (₹ 23.99 Crores)**
- Finance Cost **down at ₹ 17.33 Crores** from ₹ **20.24 Crores in FY16 (Annualized Basis)**
- Net Profit at ₹ **-4.68 Crores**, factors one-time write-offs of ₹ **4.14 Crores**

## Business Review and Strategy

- Received 48 Product Approvals in FY17 and expect 65 Product Approvals in FY18 for ROW Markets
- 93 Product Filling planned in FY18 for ROW Markets
- Launched New Domestic Marketing Division of Generic Products.
- Focus on Research for NDDS in Injections and Topical Preparations
- Commercialization of R&D Capabilities by licensing products in leading domestic and international pharmaceutical companies

## About Lyka Labs Limited

Lyka Labs Limited (BSE-LYKALABS/500259: NSE-LYKALABS) is a leading pharmaceutical company with strong capabilities in Sterile Preparations and Dermatology. It has a wide portfolio of 20+ Lyophilized Products and 50+ products in Dermatology. Its products are marketed across 46 markets globally. From its R&D Centre in Mumbai, Lyka is currently working on development of a wide range of New Formulations and New Drug Delivery System in its focus areas of Lyophilization and Dermatology and has a portfolio of over 20 products under development

### For Queries, Please Contact

#### Lyka Labs Limited

##### Yogesh Shah

Chief Financial Officer

Tel: +91 22 66112200

[ybshah@lykalabs.com](mailto:ybshah@lykalabs.com)

##### Registered Office

Lyka Labs Limited

4801/B & 4802/A

G.I.D.C. Industrial Estate,

Ankleshwar – 393 002

##### Corporate Information

**BSE Code:** 500259

**NSE Code:** LYKALABS

**Website:** [www.lykalabs.com](http://www.lykalabs.com)

**CIN:** L24230GJ1976PLC008738

##### Piyush Hindia

Company Secretary

Tel: +91 22 66112200

[companysecretary@lykalabs.com](mailto:companysecretary@lykalabs.com)

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Lyka Labs Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances